CBST : Analysis & Opinions

  1. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  2. Biotech Stock Roundup: Amgen Data Looks Good, CANF Tumbles - ...

    January 8, 2014
    Biotech Stock Roundup: Amgen Data Looks Good, CANF Tumbles - Industry Outlook
  3. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  4. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
  5. Positive Data on Novartis' Jakavi - Analyst Blog

    June 18, 2013
    Novartis recently presented positive results on oncology drug Jakavi from a three-year follow up analysis of a phase III ...
  6. MannKind Completes Afrezza Studies - Analyst Blog

    June 18, 2013
    MannKind completed a phase III study on its diabetes candidate Afrezza.
  7. Encouraging Data on Novartis' Gilenya - Analyst Blog

    June 14, 2013
    Novartis recently presented new data on Gilenya from a phase III study, TRANSFORMS.
  8. Incyte's Jakafi Label Updated - Analyst Blog

    June 13, 2013
    The FDA updated Incyte's sole marketed product Jakafi's label.
  9. Loss Widens at Alnylam, Sales Fall - Analyst Blog

    February 8, 2013
    Alnylam Pharmaceuticals Inc.'s (ALNY) fourth quarter 2012 loss of $1.20 per share was narrower than the Zacks Consensus Estimate ...
  10. Cubist: Another Solid Quarter? - Analyst Blog

    January 22, 2013
    We expect Cubist Pharmaceuticals Inc. (CBST) to beat expectations when it releases its fourth-quarter 2012 results on Jan ...
  11. Optimer's Dificid Sales Look Good - Analyst Blog

    January 9, 2013
    Optimer Pharmaceuticals Inc. (OPTR) recently announced its preliminary sales for the fourth quarter and full year 2012. ...
  12. Top Stocks with Big Potential Catch-Up Moves - Screen of the ...

    January 2, 2013
    Given the recent run-up in the market, here's a screen I've been using recently for my own stock picking. First, it focuses ...
  13. Cubist Pharma Seeks Label Expansion - Analyst Blog

    December 24, 2012
    Cubist Pharmaceuticals Inc. (CBST) announced that it has filed for the approval of its drug Entereg (alvimopan) for an additional ...
  14. Good News for Cubist Pharma - Analyst Blog

    December 7, 2012
    Cubist Pharmaceuticals Inc. (CBST) received some encouraging news recently when the US Food and Drug Administration (FDA) ...
  15. Revenues Decline at Alnylam - Analyst Blog

    November 7, 2012
    Alnylam Pharmaceuticals Inc.'s (ALNY) third quarter 2012 net loss of 38 cents per share was wider than the year-ago loss ...
  16. Edwards Lifesciences Among Healthcare's Biggest Movers on September ...

    September 24, 2012
    The Nasdaq has fallen 0.7%, the S&P 500 has fallen 0.2% and the Dow has declined 0.2% on a bad morning for the market. The ...
  17. Alnylam Presents Data on ALN-RSV01 - Analyst Blog

    September 6, 2012
    Alnylam Pharmaceuticals, Inc. (ALNY) recently presented complete results from a phase IIb trial on ALN-RSV01 at the European ...
  18. Alnylam & Monsanto Collaborate - Analyst Blog

    August 29, 2012
    Alnylam Pharmaceuticals, Inc. (ALNY) and Monsanto Company (MON) recently formed a strategic alliance to implement biological ...
  19. Alnylam Earns Milestone Payment - Analyst Blog

    August 6, 2012
    Alnylam Pharmaceuticals Inc. (ALNY) recently earned development milestone payment of $3.2 million from GlaxoSmithKline (GSK). ...
  20. Why Small May Be Better in Pharma

    July 28, 2011
    Health care’s rebound has been very kind to drugmakers in general, but as Mark Skousen of Turnaround Trader explains ...
  21. Small/Mid Cap Stocks to Watch

    April 15, 2010
    While all eyes are on the large cap stocks reporting earnings, investors can profit from these small and mid cap finds.
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center